Cyclooxygenase-dependent tumor growth through evasion of immunity.
Authors
Zelenay, Santiagovan der Veen, A
Böttcher, J
Snelgrove, K
Rogers, N
Acton, S
Chakravarty, P
Girotti, Maria Romina
Marais, Richard
Quezada, S
Sahai, E
Reis E Sousa, C
Affiliation
Immunobiology Laboratory, The Francis Crick Institute, Lincoln's Inn Fields Laboratory, 44 Lincoln's Inn Fields, London WC2A 3LY, UKIssue Date
2015-09-10
Metadata
Show full item recordAbstract
The mechanisms by which melanoma and other cancer cells evade anti-tumor immunity remain incompletely understood. Here, we show that the growth of tumors formed by mutant Braf(V600E) mouse melanoma cells in an immunocompetent host requires their production of prostaglandin E2, which suppresses immunity and fuels tumor-promoting inflammation. Genetic ablation of cyclooxygenases (COX) or prostaglandin E synthases in Braf(V600E) mouse melanoma cells, as well as in Nras(G12D) melanoma or in breast or colorectal cancer cells, renders them susceptible to immune control and provokes a shift in the tumor inflammatory profile toward classic anti-cancer immune pathways. This mouse COX-dependent inflammatory signature is remarkably conserved in human cutaneous melanoma biopsies, arguing for COX activity as a driver of immune suppression across species. Pre-clinical data demonstrate that inhibition of COX synergizes with anti-PD-1 blockade in inducing eradication of tumors, implying that COX inhibitors could be useful adjuvants for immune-based therapies in cancer patients.Citation
Cyclooxygenase-dependent tumor growth through evasion of immunity. 2015, 162 (6):1257-70 CellJournal
CellDOI
10.1016/j.cell.2015.08.015PubMed ID
26343581Type
ArticleLanguage
enISSN
1097-4172ae974a485f413a2113503eed53cd6c53
10.1016/j.cell.2015.08.015
Scopus Count
Collections
Related articles
- Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD-1 antibody for BRAF-mutated melanoma.
- Authors: Nakamura K, Yaguchi T, Murata M, Ota Y, Mikoshiba A, Kiniwa Y, Okuyama R, Kawakami Y
- Issue date: 2024 Sep
- Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
- Authors: Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A
- Issue date: 2016 Oct
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
- Authors: Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ
- Issue date: 2013 Mar
- HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAF(V600E)-mutant microsatellite stable colorectal cancer.
- Authors: Sun Z, Shi M, Xia J, Li X, Chen N, Wang H, Gao Z, Jia J, Yang P, Ji D, Gu J
- Issue date: 2025 Jan 11
- Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
- Authors: Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett DR, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM
- Issue date: 2021 May